Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Novartis
Cantor Fitzgerald
Merck
Colorcon
Fish and Richardson
Healthtrust
Deloitte
Chubb
Accenture

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,968,914

« Back to Dashboard

Summary for Patent: 5,968,914
Title: Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
Abstract:The subject invention discloses compounds, compositions and methods for treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivatives of non-methylated pyrimidine nucleosides. These compounds are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy.
Inventor(s): von Borstel; Reid (Potomac, MD), Bamat; Michael K. (Potomac, MD)
Assignee: Pro-Neuron, Inc. (Rockville, MD)
Application Number:08/472,210
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 5,968,914

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Wellstat Therap VISTOGARD uridine triacetate GRANULE;ORAL 208159-001 Dec 11, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe EMERGENCY TREATMENT OF ADULT & PEDIATRIC PATIENTS FOLLOWING FLUOROURACIL OR CAPECITABINE OVERDOSE,OR WHO EXHIBIT EARLY-ONSET,SEVERE OR LIFE-THREATENING CARDIAC OR CNS TOXICITY OR UNUSUALLY SEVERE ADVERSE REACTIONS WITHIN 96 HOURS ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 5,968,914

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,919,320 Pharmaceutical compositions containing deoxyribonucleosides for wound healing ➤ Subscribe
6,232,298 Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis ➤ Subscribe
6,306,834 Acyl deoxyribonucleoside derivatives and uses thereof ➤ Subscribe
6,060,459 Enhancing blood cell count with oxypurine nucleosides ➤ Subscribe
5,246,708 Methods for promoting wound healing with deoxyribonucleosides ➤ Subscribe
6,743,782 Acyl deoxyribonucleoside derivatives and uses thereof ➤ Subscribe
7,307,166 Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis ➤ Subscribe
7,776,838 Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides ➤ Subscribe
6,297,222 Acyl deoxyribonucleoside derivatives and uses thereof ➤ Subscribe
6,344,447 Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,968,914

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 142221 ➤ Subscribe
Austria 179615 ➤ Subscribe
Austria 205850 ➤ Subscribe
Austria 243039 ➤ Subscribe
Austria 282627 ➤ Subscribe
Austria 320813 ➤ Subscribe
Austria 93236 ➤ Subscribe
Austria 97574 ➤ Subscribe
Australia 1417792 ➤ Subscribe
Australia 2254492 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Cantor Fitzgerald
Harvard Business School
McKesson
Boehringer Ingelheim
Novartis
Fish and Richardson
AstraZeneca
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot